Holen Sie sich die Stockscreener-App
203.04
3.02%
5.96
Handel nachbörslich:
202.00
-1.04
-0.51%
Schlusskurs vom Vortag:
$197.08
Offen:
$199.73
24-Stunden-Volumen:
1.55M
Relative Volume:
1.15
Marktkapitalisierung:
$28.31B
Einnahmen:
$2.12B
Nettoeinkommen (Verlust:
$-309.19M
KGV:
-88.89
EPS:
-2.2841
Netto-Cashflow:
$93.57M
1W Leistung:
-12.16%
1M Leistung:
-18.37%
6M Leistung:
+46.99%
1J Leistung:
+15.93%
1-Tages-Spanne:
$194.02
$203.68
1-Wochen-Bereich:
$194.02
$236.58
52-Wochen-Spanne:
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
203.04 | 27.48B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
542.83 | 203.77B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.61 | 152.51B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
644.61 | 51.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
129.58 | 36.75B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
187.49 | 30.69B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Earnings Miss: What are analysts price targets for Natera Inc2025 Market Overview & Pattern Based Trade Signal System - baoquankhu1.vn
Is Natera (NTRA) Quietly Redefining Its Moat With Multi-Front Cell-Free DNA Expansion? - simplywall.st
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes - Yahoo Finance
This brand-new Peninsula building sat vacant for a year. Now it's landed two big tenants - The Business Journals
News | Genetic testing firm inks deal at Silicon Valley life science campus - CoStar
Natera CEO sells $20.7 million in NTRA stock By Investing.com - Investing.com South Africa
Natera sec. and chief legal officer sells $307k in stock By Investing.com - Investing.com Nigeria
Natera sec. and chief legal officer sells $307k in stock - Investing.com UK
Natera director Sheena Jonathan sells $100k in stock By Investing.com - Investing.com Australia
Natera CFO Brophy sells $1.58 million in NTRA stock By Investing.com - Investing.com Canada
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock By Investing.com - Investing.com Nigeria
Natera Inc. president Fesko sells $830k in stock By Investing.com - Investing.com Nigeria
Natera CEO sells $20.7 million in NTRA stock - Investing.com
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock - Investing.com
Oversold Conditions For Natera (NTRA) - Nasdaq
Natera Inc (NTRA) Stock Price Down 7.82% on Feb 4 - GuruFocus
Principal Financial Group Inc. Has $69.11 Million Stake in Natera, Inc. $NTRA - MarketBeat
National Pension Service Invests $1.49 Million in Natera, Inc. $NTRA - MarketBeat
Trading Systems Reacting to (NTRA) Volatility - Stock Traders Daily
Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test - The Globe and Mail
Exploring US High Growth Tech Stocks This February 2026 - simplywall.st
Natera submits FDA approval for bladder cancer test By Investing.com - Investing.com Nigeria
Natera Files FDA PMA for Signatera CDx in Muscle-Invasive Bladder Cancer - Oncodaily
Natera, Inc. (NTRA) Stock Analysis: Potential Growth Amidst Strong Analyst Confidence - DirectorsTalk Interviews
FDA premarket approval sought for Signatera CDx test in MIBC - Urology Times
Natera Submits Signatera™ CDx PMA to FDA - MEXC
Natera Submits Premarket Approval Application for Molecular Residual Disease Test Signatera CDx - marketscreener.com
NTRA Submits PMA to FDA for Bladder Cancer Detection Innovation - GuruFocus
Natera submits Signatera(TM) CDx PMA to FDA - marketscreener.com
Natera submits FDA approval for bladder cancer test - Investing.com
Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Inflation Data: Is now the right time to enter Natera IncQuarterly Portfolio Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Natera, Inc. $NTRA Shares Purchased by New York State Common Retirement Fund - MarketBeat
$8.25M Natera prenatal screening class action settlement - Class Action Lawsuits
Short Interest in Natera, Inc. (NASDAQ:NTRA) Declines By 27.2% - MarketBeat
A Look At The Fair Value Of Natera, Inc. (NASDAQ:NTRA) - Yahoo Finance
Natera, Inc. $NTRA Shares Purchased by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 2,413 Shares of Stock - MarketBeat
Michael Burkes Brophy Sells 1,867 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Natera (NASDAQ:NTRA) CFO Sells $188,575.52 in Stock - MarketBeat
Natera (NASDAQ:NTRA) CEO Sells $866,983.68 in Stock - MarketBeat
Natera CFO Brophy sells $1.19 million in shares By Investing.com - Investing.com South Africa
Natera CEO sells $1.4m in NTRA stock By Investing.com - Investing.com Nigeria
Natera CEO sells $1.4m in NTRA stock - Investing.com
Natera (NASDAQ:NTRA) Insider Sells $285,192.00 in Stock - MarketBeat
Natera (NASDAQ:NTRA) Insider John Fesko Sells 928 Shares - MarketBeat
Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 784 Shares of Stock - MarketBeat
Natera co-founder Sheena Jonathan sells $115k in stock By Investing.com - Investing.com South Africa
Natera president sells $528k in NTRA stock By Investing.com - Investing.com South Africa
Natera president sells $528k in NTRA stock - Investing.com
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
3.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):